Hazzan M - Search Results

1

Hamroun A, Frimat M, Beuscart JB, Buob D, Lionet A, Lebas C, Daroux M, Provôt F, Hazzan M, Boulanger É, Glowacki F. Hamroun A, et al. Among authors: hazzan m. Nephrol Ther. 2019 Dec;15(7):533-552. doi: 10.1016/j.nephro.2019.10.001. Epub 2019 Nov 9. Nephrol Ther. 2019. PMID: 31711751 Review. French.

2

Improvement in long-term graft survival in cadaveric renal transplant recipients treated with mycophenolate mofetil.

Hazzan M, Provot F, Glowacki F, Copin MC, Roumilhac D, Labalette M, Pruvot FR, Noel C. Hazzan M, et al. Transpl Int. 2004 Oct;17(9):525-30. doi: 10.1007/s00147-004-0739-y. Epub 2004 Aug 28. Transpl Int. 2004. PMID: 15338120 Free article.

3

Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.

Hazzan M, Labalette M, Copin MC, Glowacki F, Provôt F, Pruv FR, Noël C. Hazzan M, et al. J Am Soc Nephrol. 2005 Aug;16(8):2509-16. doi: 10.1681/ASN.2005030312. Epub 2005 Jun 29. J Am Soc Nephrol. 2005. PMID: 15987748 Clinical Trial.

4

Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial.

Hazzan M, Buob D, Labalette M, Provot F, Glowacki F, Hoffmann M, Copin MC, Noel C. Hazzan M, et al. Transplantation. 2006 Sep 15;82(5):657-62. doi: 10.1097/01.tp.0000229424.11872.a0. Transplantation. 2006. PMID: 16969289 Clinical Trial.

5

[Immunosuppressive strategies and chronic graft dysfunction in kidney transplantation].

Hazzan M, Glowacki F, Lionet A, Provot F, Noël C. Hazzan M, et al. Nephrol Ther. 2008 Oct;4 Suppl 3:S208-13. doi: 10.1016/S1769-7255(08)74237-8. Nephrol Ther. 2008. PMID: 19000889 Review. French.

6

Long-term kinetics of a T-lymphocytes subset in kidney transplant recipients: relationship with posttransplant malignancies.

Glowacki F, Al Morabiti M, Lionet A, Labalette M, Provot F, Noel C, Hazzan M. Glowacki F, et al. Among authors: hazzan m. Transplant Proc. 2009 Oct;41(8):3323-5. doi: 10.1016/j.transproceed.2009.09.033. Transplant Proc. 2009. PMID: 19857742

7

[Minimize kidney failure in transplantation patients with proliferation signal inhibitors].

Glowacki F, Dharancy S, Noël C, Hazzan M. Glowacki F, et al. Among authors: hazzan m. Gastroenterol Clin Biol. 2009 Nov;33 Suppl 4:S253-6. doi: 10.1016/S0399-8320(09)73162-8. Gastroenterol Clin Biol. 2009. PMID: 20004331 Free article. French.

8

[Weaning from corticosteroid therapy after kidney transplantation].

Hazzan M, Glowacki F, Lionet A, Provôt F, Noël C. Hazzan M, et al. Nephrol Ther. 2009 Dec;5 Suppl 6:S355-8. doi: 10.1016/S1769-7255(09)73425-X. Nephrol Ther. 2009. PMID: 20129445 French.

9

An exceptional minute tumour incidentally found in a renal biopsy.

Buob D, Copin MC, Perez T, Hachulla E, Hazzan M, Leroy X. Buob D, et al. Among authors: hazzan m. Nephrol Dial Transplant. 2011 Apr;26(4):1436-8. doi: 10.1093/ndt/gfq836. Epub 2011 Feb 15. Nephrol Dial Transplant. 2011. PMID: 21324975

10

Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients.

Glowacki F, Lionet A, Hammelin JP, Labalette M, Provôt F, Hazzan M, Broly F, Noël C, Cauffiez C. Glowacki F, et al. Among authors: hazzan m. Clin Pharmacokinet. 2011 Jul;50(7):451-9. doi: 10.2165/11587050-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21528942

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

167 results

Search Page